WO1998027108A2 - Nouveaux composes amide - Google Patents

Nouveaux composes amide Download PDF

Info

Publication number
WO1998027108A2
WO1998027108A2 PCT/JP1997/004243 JP9704243W WO9827108A2 WO 1998027108 A2 WO1998027108 A2 WO 1998027108A2 JP 9704243 W JP9704243 W JP 9704243W WO 9827108 A2 WO9827108 A2 WO 9827108A2
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
group
phenyl
alkyl
nmr
Prior art date
Application number
PCT/JP1997/004243
Other languages
English (en)
Other versions
WO1998027108A3 (fr
Inventor
Yoshikuni Itoh
Takayuki Inoue
Hitoshi Hamashima
Ichiro Shima
Kazuhiko Ohne
Kousei Yoshihara
Teruo Oku
Takumi Yatabe
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
YATABE, Yoshiko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO4219A external-priority patent/AUPO421996A0/en
Priority claimed from AUPO5929A external-priority patent/AUPO592997A0/en
Priority claimed from AUPO9030A external-priority patent/AUPO903097A0/en
Application filed by Fujisawa Pharmaceutical Co., Ltd., YATABE, Yoshiko filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to JP52752898A priority Critical patent/JP2001505585A/ja
Priority to AU49680/97A priority patent/AU4968097A/en
Priority to EP97912529A priority patent/EP0946587A2/fr
Publication of WO1998027108A2 publication Critical patent/WO1998027108A2/fr
Publication of WO1998027108A3 publication Critical patent/WO1998027108A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • TECHNICAL FIELD This invention relates to new amide compounds and pharmaceutically acceptable salts thereof which are useful as medicament.
  • This invention relates to new amide compounds.
  • One object of this invention is to provide the new and useful amide compounds and pharmaceutically acceptable salts thereof which possess a strong inhibitory activity on the production of nitric oxide (NO).
  • Another object of this invention is to provide a process for the preparation of the amide compounds and salts thereof.
  • a further object of this invention is to provide a pharmaceutical composition comprising said amide compound or a pharmaceutically acceptable salt thereof.
  • Still further object of this invention is to provide a use of said amide compounds or pharmaceutically acceptable salts thereof as a medicament for prophylactic and therapeutic treatment of NO-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock (e.g., septic shock, etc.), diabetes (e.g., insulin-dependent diabetes mellitus, etc.), diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease (e.g., ulcerative colitis, chronic colitis, etc.), cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, postherpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, derma
  • R 1 is indolyl which may have a suitable substituent selected from the group consisting of lower alkyl, phenyl, halogen, lower alkoxy, and nitro, benzofuranyl, phenyl which may have one or two suitable substituent(s) selected from the group consisting of amino, acylamino, lower alkylamino, halogen, lower alkoxy and nitro, lower alkyl, quinoxalinyl, quinolyl, pyrrolyl, pyrimidinyl having benzofuranyl, benzimidazolyl, benzothienyl, benzothiazolyl, benzoxazolyl, indolinyl, anilino, phenylcarbaoyl or imidazolyl which may have one or two suitable substituent(s) selected from the group consisting of phenyl, lower alkyl and indolyl;
  • R 2 is hydrogen or phenyl(lower)alkyl
  • R* is hydrogen, phenyl or pyridyl, each of which may have suitable substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, lower alkylthio, halogen, trihalomethyl, nitro, cyano, imidazolyl, optionally protected hydroxy, acyl, amino, acylamino, diacylamino, di(lower)alkylamino, amino(lower)alkyl, acylamino(lower)alkyl, pyrazolyl, morpholinyl, piperidyl, triazolyl, lower alkoxy(lower)alkoxy, hydroxy(lower)alkyl, lower alkylpiperazinyl, phenyl and carboxy, quinolyl or 3,4-methylenedioxyphenyl;
  • R 5 is hydrogen, imidazolyl, phenyl, nitrophenyl, phenyl(lower)alkyl, optionally esterified carboxy or a group of the formula
  • R 7 and R 8 are the same or different and each is hydrogen, phenyl, phenyl(lower)alkyl, lower alkyl or lower alkoxy; or
  • Y is a group of the formula
  • R 3 is hydrogen or a group of the formula -(CH 2 ) consult-R 6 in which R 6 is optionally protected hydroxy, acyl, carboxy, acylamino, lower alkoxy, phenyl(lower)alkoxy, lower alkylthio, phenyl which may have a suitable substituent selected from the group consisting of lower alkoxy, halogen, amino, acylamino, diacylamino and nitro, pyridyl which may have a suitable substituent selected from the group consisting of lower alkoxy and halogen, pyrazinyl, pyrimidinyl, furyl, imidazolyl, naphthyl, N-(lower)- alkylindolyl or 3,4-methylenedioxyphenyl, and n is an integer of 0 to 3, or a group of the formula
  • R 11 is phenyl, phenoxy or phenyl(lower)alkoxy; or R 2 and R 3 in combination form a group of the formula
  • R 1 ° is hydrogen, lower alkyl or lower alkoxy; or a pharmaceutically acceptable salt thereof, provided that the compound shown below is excluded: a compound of the formula
  • R 1 ' is indolyl or benzofuranyl
  • R 2 ' is hydrogen, lower alkylthio(lower)alkyl or a group of the formula
  • R 5 ' is hydrogen, lower alkoxy or halogen
  • R 3 ' is hydrogen, quinolyl or phenyl which may have a suitable substituent selected from the group consisting of lower alkyl, lower alkoxy, lower alkylthio and halogen
  • R*' is hydrogen or optionally esterified carboxy
  • X' is S or NR 6 ' in which R 6 ' is hydrogen, lower alkyl or a group of the formula - CH2 - ⁇ JT
  • R 7 ' is lower alkyl or lower alkoxy, and a pharmaceutically acceptable salt thereof.
  • Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and include, for example, a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.
  • an inorganic acid addition salt e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.
  • an organic carboxylic or sulfonic acid addition salt e.g., formate, acetate, trifluoroacetate, maleate, tartrate, citrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.
  • a salt with a basic or acidic amino acid e.g., arginine, aspartic acid, gultamic acid, etc.
  • lower is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
  • Suitable "lower alkoxy” and “lower alkoxy moiety" in the terms “lower alkoxy(lower)alkoxy” and “phenyl(lower) lkoxy” include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, tert-pentyloxy and hexyloxy, in which more preferred one is Ci-C* alkoxy.
  • Suitable "halogen” includes, for example, fluorine, bromine, chlorine and iodine.
  • Optionally esterified carboxy includes carboxy and esterified carboxy. Suitable examples of said ester include lower alkyl ester (e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, tert-pentyl ester, hexyl ester, etc.); lower alkenyl ester (e.g., vinyl ester, allyl ester, etc.); lower alkynyl ester (e.g., ethynyl ester, propynyl ester, etc.); lower alkoxy(lower)alkyl ester (e.g., methoxymethyl ester, ethoxymethyl ester, isopropoxymethyl ester, 1 -methoxyethyl ester, 1 -ethoxyethyl ester, etc.); mono(or
  • Suitable "trihalomethyl” includes, for example, trifluoromethyl, trichloromethyl and tribromomethyl, in which preferred one is trifluoromethyl.
  • Suitable “amino protective group” includes, for example, acyl and conventional protective group such as mono(or di or tri)aryl(lower)- alkyl, for example, mono(or di or tri)phenyl(lower)alkyl (e.g., benzyl, trityl, etc.).
  • acyl and “acyl moiety” in the terms “acylamino”, “diacylamino” and “acylamino(lower)alkyl” include, for example, carbamoyl which may be substituted by suitable substituent(s), aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl, or a heterocyclic ring, which is referred to as heterocyclic acyl.
  • acyl which may be substituted by suitable substituent(s)
  • substituent(s) includes a group of the formula
  • R 12 and R 13 are the same or different and each is hydrogen, lower alkyl, phenyl which may have a suitable substituent selected from the group consisting of lower alkoxy and halogen, phenyl(lower)- alkyl, pyridyl, pyridyl(lower)alkyl or 3,4-methylenedioxyphenyl; aliphatic acyl such as lower alkanoyl which may be substituted by one to three halogen atoms (e.g., formyl, acetyl, propanoyl, butanoyl, 2- methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, trichloroacetyl, trifluoroacetyl, etc.), lower alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, tert- pentyl
  • naphthyl(lower)alkanoyl e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.
  • aryl(lower)alkoxycarbonyl e.g., phenyl(lower)alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), etc.
  • aryloxycarbonyl e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc.
  • aryloxy(lower)alkanoyl e.g., phenoxyacetyl, phenoxypropionyl, etc.
  • arylsulfonyl e.g., phenylsulfonyl, p-tolylsufonyl, etc.
  • heterocyclic acyl such as indolylcarbonyl (e.g., indolylcarbon
  • Optionally protected hydroxy includes hydroxy and protected hydroxy.
  • Suitable examples of "hydroxy protective group" in the term “protected hydroxy” include acyl (e.g., acetyl, trichloroacetyl, etc.), mono(or di or tri)phenyl(lower)alkyl which may have one or more suitable substituent(s) (e.g., benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted silyl [e.g., tri(lower)alkylsilyl (e.g., trimethylsilyl, tert-butyldimethylsilyl, etc.), etc.], tetrahydropyranyl and the like.
  • acyl e.g., acetyl, trichloroacetyl, etc.
  • mono(or di or tri)phenyl(lower)alkyl which may have one or more suitable substituent(s) (
  • Suitable "protected carboxy” is carboxy group protected by conventional protective group such as lower alkoxycarbonyl [e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, sec-butoxycarbonyl, isobutoxycarbonyl, tert- butoxycarbonyl, pentyloxycarbonyl, neopentyloxycarbonyl, hexyloxycarbonyl, etc.], optionally substituted phenyl(lower)- alkoxycarbonyl for example, mono- or di- or triphenyl(lower)- alkoxycarbonyl which may be substituted by nitro [e.g., benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, benzhydryloxycarbonyl, trityloxycarbonyl, etc.] and the like.
  • lower alkoxycarbonyl e.g., methoxycarbonyl,
  • Suitable "cyclo(lower)alkyl” includes cycloalkyl having 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, in which more preferred ones are cyclopropyl and cyclobutyl.
  • morpholinyl includes 2-morpholinyl, 3-morpholinyl and 4-morpholinyl (i.e. morpholino).
  • piperidyl includes 1 -piperidyl (i.e. piperidino), 2- piperidyl, 3-piperidyl and 4-piperidyl.
  • the object compound (I) of the present invention can be prepared by the following processes.
  • R 1 , R 2 , R ft , R 5 , R 7 , R 8 , R 9 , X, Y, m and n are each as l 7 defined above,
  • R 1 * is amino protective group
  • R 15 is hydrogen or lower alkyl
  • R 16 is acyl
  • R 1 is acylamino or diacylamino
  • R 18 is carboxy or lower alkoxycarbonyl
  • R 19 is esterified carboxy
  • R 20 is acylamino or diacylamino
  • R 21 is carbamoyl which may be substituted by suitable substituent(s)
  • R 22 is hydroxy protective group
  • R 23 is acyl
  • R 2 * is lower alkyl
  • R 25 is protected carboxy
  • R 26 is esterified carboxy
  • R 27 is carbamoyl which may be substituted by suitable substituent(s)
  • R 28 is acylamino or diacylamino
  • R 29 is acyl
  • R 30 is esterified carboxy.
  • the starting compounds can be prepared by the method of Preparation mentioned below or by a process known in the art for preparing their structually analogous compounds.
  • the compound (I) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the amino group, or a salt thereof with the compound (III) or its reactive derivative at the
  • Suitable reactive derivative of the compound (II) includes Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (II) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (II) with a silyl compound such as N,0- bis(trimethylsilyl)acetamide, N-trimethylsilylacetamide or the like; a derivative formed by the reaction of the compound (II) with phosphorus trichloride or phosgene.
  • Suitable reactive derivative of the compound (III) includes an acid halide, an acid anhydride and an activated ester.
  • the suitable example may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc.
  • the reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N- dimethylformamide, pyridine or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.
  • a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N- dimethylformamide, pyridine or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.
  • the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'- dicyclohexylcarbodiimide; N-cyclohexyl-N' -morpholinoethylcarbodiimide; N-cyclohexyl-N' -(4-diethylaminocyclohexyl)carbodiimide; N,N' - diisopropylcarbodiimide; N-ethyl-N' -(3-dimethylaminopropyl)- carbodiimide; N,N-carbonyl-bis-(2-methylimidazole) ; pentamethylene- ketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1 -alkoxy-1 -chloroethylene; trialkyl pho
  • the reaction may also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N- di(lower)alkylbenzylamine, or the like.
  • an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N- di(lower)alkylbenzylamine, or the like.
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.
  • the compound (I)-1 or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (IV).
  • the reaction can be carried out in the same manner as in or a manner similar to Example 27.
  • the compound (I)-2 or a salt thereof can be prepared by subjecting the compound (V) or a salt thereof to elimination reaction of the amino protective group.
  • Suitable method of this elimination reaction includes conventional one such as hydrolysis, reduction and the like, (i) For hydrolysis :
  • the hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
  • Suitable base includes an inorganic base and an organic base such as an alkali metal [e.g., sodium, potassium, etc.], an alkaline earth metal [e.g., magnesium, calcium, etc.], the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine [e.g., trimethylamine, triethylamine, etc.], picoline, 1 ,5-diazabicyclo[ .3.0]non-5-one, or the like.
  • an alkali metal e.g., sodium, potassium, etc.
  • an alkaline earth metal e.g., magnesium, calcium, etc.
  • trialkylamine e.g., trimethylamine, triethylamine, etc.
  • picoline 1 ,5-diazabicyclo[ .3.0]non-5-one, or the like.
  • Suitable acid includes an organic acid [e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], and an inorganic acid [e.g. , hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.].
  • organic acid e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
  • an inorganic acid e.g. , hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.
  • Lewis acid such as trihaloacetic acid [e.g., trichloroacetic acid, trifluoroacetic acid, etc.], or the like is preferably carried out in the presence of cation trapping agents [e.g., anisole, phenol, etc.]. This reaction is usually carried out without solvent.
  • the reaction may be carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
  • a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
  • reaction temperature is not critical and the reaction is usually carried out under cooling to warming, (ii) For reduction :
  • Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.
  • Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.), or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).
  • a metal e.g., tin, zinc, iron, etc.
  • metallic compound e.g., chromium chloride, chromium acetate, etc.
  • organic acid or inorganic acid e.g., formic acid, acetic acid, propionic acid,
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, palladium hydroxide on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.
  • platinum catalysts e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.
  • palladium catalysts e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, palladium hydroxide on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.
  • nickel catalysts e.g., reduced nickel, nickel oxide, Raney nickel, etc.
  • cobalt catalysts e.g., reduced cobalt, Raney cobalt, etc.
  • iron catalysts e.g., reduced iron, Raney iron, Ullman iron, etc.
  • the reduction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
  • a solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
  • alcohol e.g., methanol, ethanol, isopropyl alcohol, etc.
  • reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.
  • the compound (I)-4 or a salt thereof can be prepared by reacting the compound (I) ⁇ 3 or its reactive derivative at the amino group, or a salt thereof with the compound (VI) or its reactive derivative at the carboxy group, or a salt thereof.
  • This reaction can be carried out in a similar manner to the reaction in the aforementioned Process (1 ) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process ⁇ .
  • the reaction conditions e.g., solvent, reaction temperature, etc.
  • the compound (I)-6 or a salt thereof can be prepared by subjecting the compound (I)-5 or a salt thereof to reduction.
  • the reduction can be carried out in the same manner as in or a manner similar to Example 60.
  • the compound (I)-7 or a salt thereof can be prepared by subjecting the compound (I)-6 or a salt thereof to acylation.
  • the acylation can be carried out in the same manner as in or a manner similar to Example 61.
  • the compound (I)-9 or a salt thereof can be prepared by subjecting the compound (I)-8 or a salt thereof to reduction.
  • the reduction can be carried out in the same manner as in or a manner similar to Example 111.
  • the compound (I)-10 or a salt thereof can be prepared by subjecting the compound (I)-9 or a salt thereof to oxidation.
  • the oxidation can be carried out in the same manner as in or a manner similar to Example 112.
  • the compound (I)-12 or a salt thereof can be prepared by subjecting the compound (I)-11 or a salt thereof to hydrolysis.
  • the hydrolysis can be carried out in the same manner as in or a manner similar to Example 113.
  • the compound (I)-14 or a salt thereof can be prepared by subjecting the compound (I)-13 or a salt thereof to reduction.
  • the reduction can be carried out in the same manner as in or a manner similar to Example 123.
  • the compound (I)-15 or a salt thereof can be prepared by subjecting the compound (I)-14 or a salt thereof to acylation.
  • the acylation can be carried out in the same manner as in or a manner similar to Example 124.
  • the compound (I)-16 or a salt thereof can be prepared by subjecting the compound (I)-12 or a salt thereof to amidation.
  • the compound (I)-18 or a salt thereof can be prepared by subjecting the compound (I)-17 or a salt thereof to elimination reaction of the hydroxy protective group.
  • This reaction can be carried out in a similar manner to the reaction in the aforementioned Process (3) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc. ) can be referred to those of the Process (3).
  • the reaction conditions e.g., solvent, reaction temperature, etc.
  • the compound (I)-19 or a salt thereof can be prepared by subjecting the compound (I)-18 or a salt thereof to esterification.
  • the esterification can be carried out in the same manner as in or a manner similar to Example 133.
  • the compound (I)-20 or a salt thereof can be prepared by subjecting the compound (I)-18 or a salt thereof to 0-alkylation.
  • the 0-alkylation can be carried out in the same manner as in or a manner similar to Example 135.
  • the compound (I)-22 or a salt thereof can be prepared by subjecting the compound (I)-21 or a salt thereof to elimination reaction of the carboxy protective group.
  • This reaction can be carried out in a similar manner to the reaction in the aforementioned Process (3) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (3).
  • the reaction conditions e.g., solvent, reaction temperature, etc.
  • the compound (I)-23 or a salt thereof can be prepared by subjecting the compound (I)-22 or a salt thereof to esterification.
  • the esterification can be carried out in the same manner as in or a manner similar to Example 74.
  • the compound (I)-24 or a salt thereof can be prepared by subjecting the compound (I)-22 or a salt thereof to amidation.
  • the amidation can be carried out in the same manner as in or a manner similar to Example 95.
  • the compound (I)-26 or a salt thereof can be prepared by subjecting the compound (I)-25 or a salt thereof to reduction.
  • the reduction can be carried out in the same manner as in or a manner similar to Example 119.
  • the compound (I)-27 or a salt thereof can be prepared by subjecting the compound (I)-26 or a salt thereof to acylation.
  • the acylation can be carried out in the same manner as in or a manner similar to Example 120.
  • the compound (I)-29 or a salt thereof can be prepared by subjecting the compound (I)-28 or a salt thereof to esterification.
  • the esterification can be carried out in the same manner as in or a manner similar to Example 138.
  • the compound (I)-31 or a salt thereof can be prepared by subjecting the compound (I)-30 or a salt thereof to hydrolysis.
  • the hydrolysis can be carried out in the same manner as in or a manner similar to Example 168.
  • the compound (I)-32 or a salt thereof can be prepared by reacting the compound (I)-31 or its reactive derivative at the carboxy group, or a salt thereof with the compound (VII) or its reactive derivative at the amino group, or a salt thereof.
  • This reaction can be carried out in a similar manner to the reaction in the aforementioned Process (1 ) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process
  • the compound (I)-33 can be prepared by reacting the compound (VIII) with the compound (IX) in the presence of an acid.
  • This reaction can be carried out in the same manner as in or a manner similar to Example 178.
  • Suitable salts of the starting compounds and their reactive derivatives in Process (1) can be referred to the ones as exemplified for the compound (I).
  • the compounds obtained by the above process can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like.
  • the compound (I) and the other compounds may include one or more stereoisomer(s) such as optical isomer(s) and geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s), and all of such isomers and mixtures thereof are included within the scope of this invention.
  • the object compounds (I) and pharmaceutically acceptable salts thereof include solvates [e.g., enclosure compounds (e.g., hydrate, etc.)].
  • the object compounds (I) and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO).
  • the object compounds (I) and pharmaceutically acceptable salts thereof are expected to possess a nitric oxide synthase (NOS)-inhibitory activity or a NOS-production inhibitory activity.
  • NOS nitric oxide synthase
  • NO-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock (e.g., septic shock, etc.), diabetes (e.g., insulin-dependent diabetes mellitus, etc.), diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease (e.g., ulcerative colitis, chronic colitis, etc.), cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, postherpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, dermatitis, hepatitis, liver cirrhosis, multiple sclerosis, pancrea
  • test Compounds In order to illustrate the usefulness of the object compound (I) , the pharmacological test result of the representative compound of the compound (I) is shown in the following. Test Compounds :
  • RAW264.7 American Type Culture Collection, No. TTB71
  • DMEM Dulbecco's modified Eagle's medium
  • penicillin, streptomycin and 10$ heat-inactivated fetal bovine serum were removed from culture flasks by rubber cell scraper and were centrifuged and resuspended in DMEM without phenol red. They were plated in 96-well microtiter plates (10 5 cells per well) and allowed to adhere over 2 hours.
  • test samples were added and the cells were preincubated for 1 hour. Thereafter the cells were activated with both of lipopolysaccharide (LPS) (1/zg/ml) and interferon ⁇ (INF ) (3 u/ml) for 18-24 hours.
  • LPS lipopolysaccharide
  • INF interferon ⁇
  • An equal volume of Griess reagent ( ] % sulfanilamide/0.1/ ⁇ N-naphthylethylenediamine dihydrochloride/2.5% H3PO1*) was added and the cells were incubated at room temperature for 10 minutes. The absorbance was read at 570 nm using microplate reader and NO ⁇ " was measured using NaNO ⁇ as a standard.
  • the object compound (I) of the present invention and pharmaceutically acceptable salts thereof are used in the form of a conventional pharmaceutical preparation in admixture with a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
  • a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
  • the pharmaceutical preparation may be compounded in a solid form such as granule, capsule, tablet, dragee, suppository or ointment, or in a liquid form such as solution, suspension or emulsion for injection, intravenous drip, ingestion, eye drop, etc.
  • auxiliary substance such as stabilizing agent, wetting or emulsifying agent, buffer or any other commonly used additives.
  • the effective ingredient may usually be administered in a unit dose of 0.001 mg/kg to 500 mg/kg, preferably 0.01 mg/kg to 10 mg/kg, 1 to 4 times a day.
  • the above dosage may be increased or decreased according to age, body weight and conditions of the patient or administering method.
  • R 1 is indolyl which may have a suitable substituent selected from the group consisting of lower alkyl, phenyl, halogen, lower alkoxy, and nitro, benzofuranyl, phenyl which may have one or two
  • R 2 is hydrogen or phenyl(lower)alkyl
  • R* is phenyl or pyridyl, each of which has suitable substituent(s) selected from the group consisting of trihalomethyl, nitro, cyano, imidazolyl, optionally protected hydroxy, acyl, amino, acylamino, diacylamino, di(lower)alkylamino, amino(lower)alkyl, acylamino(lower)alkyl, pyrazoly1, morpholinyl, piperidyl, triazolyl, lower alkoxy(lower)alkoxy, hydroxy(lower)alkyl, lower alkylpiperazinyl, phenyl and carboxy, or 3, -methylenedioxyphenyl;
  • R 5 is hydrogen, imidazolyl, phenyl, nitrophenyl, phenyl(lower)alkyl, optionally esterified carboxy or a group of the formula
  • R 7 and R 8 are the same or different and each is hydrogen, phenyl, phenyl(lower)alkyl, lower alkyl or lower alkoxy; or
  • Y is a group of the formula
  • R 6 is optionally protected hydroxy, acyl, carboxy, acylamino, lower alkoxy, phenyl(lower) lkoxy, lower alkylthio, phenyl which may have a suitable substituent selected from the group consisting of lower alkoxy, halogen, amino, acylamino, diacylamino and nitro, pyridyl which may have a suitable substituent selected from the group consisting of lower alkoxy and halogen, pyrazinyl, pyrimidinyl, furyl, imidazolyl, naphthyl, N-(lower)- alkylindolyl or 3,4-methylenedioxyphenyl, and n is an integer of 0 to 3, or a group of the formula
  • R 1 ' is phenyl, phenoxy or phenyl(lower)alkoxy; or R 2 and R 3 in combination form a group of the formula
  • R 1 ° is hydrogen, lower alkyl or lower alkoxy; or a pharmaceutically acceptable salt thereof.
  • R 1 is indolyl which has a suitable substituent selected from the group consisting of lower alkyl, phenyl, halogen, lower alkoxy, and nitro, phenyl which may have one or two suitable substituent(s) selected from the group consisting of amino, acylamino, lower alkylamino, halogen, lower alkoxy and nitro, lower alkyl, quinoxalinyl, quinolyl, pyrrolyl, pyrimidinyl having benzofuranyl, benzimidazolyl, benzothienyl, benzothiazolyl, benzoxazolyl, indolinyl, anilino, phenylcarbamoyl or imidazolyl which may have one or two suitable substituent(s) selected from the group consisting of phenyl, lower alkyl and indolyl;
  • R 2 is hydrogen or phenyl(lower)alkyl
  • R ft is hydrogen, phenyl or pyridyl, each of which may have suitable substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, lower alkylthio and halogen or quinolyl;
  • R 5 is hydrogen, imidazolyl, phenyl, nitrophenyl, phenyl(lower)alkyl, optionally esterified carboxy or a group of the formula
  • R 7 and R 8 are the same or different and each is hydrogen, phenyl, phenyl(lower)alkyl, lower alkyl or lower alkoxy; or
  • Y is a group of the formula
  • R 6 is optionally protected hydroxy, acyl, carboxy, acylamino, lower alkoxy, phenyl(lower)alkoxy, lower alkylthio, phenyl which may have a suitable substituent selected from the group consisting of lower alkoxy, halogen, amino, acylamino, diacylamino and nitro, pyridyl which may have a suitable substituent selected from the group consisting of lower alkoxy and halogen, pyrazinyl, pyrimidinyl, furyl, imidazolyl, naphthyl, N-(lower)- alkylindolyl or 3,4-methylenedioxyphenyl, and n is an integer of 0 to 3, or a group of the formula
  • R 1 ' is phenyl, phenoxy or phenyl(lower)alkoxy; or R 2 and R 3 in combination form a group of the formula
  • R 1 ° is hydrogen, lower alkyl or lower alkoxy; or a pharmaceutically acceptable salt thereof.
  • R 1 is indolyl or benzofuranyl
  • R 2 is hydrogen or phenyl(lower) lkyl
  • R* is hydrogen, phenyl or pyridyl, each of which may have suitable substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, lower alkylthio and halogen or quinolyl;
  • R 5 is hydrogen, imidazolyl, phenyl, nitrophenyl, phenyl(lower)alkyl, optionally esterified carboxy or a group of the formula
  • R 7 and R 8 are the same or different and each is hydrogen, phenyl, phenyl(lower)alkyl, lower alkyl or lower alkoxy; or
  • Y is a group of the formula
  • R 3 is a group of the formula in which R 6 is optionally protected hydroxy, acyl, carboxy, acylamino, lower alkoxy, phenyl(lower)alkoxy, phenyl which has a suitable substituent selected from the group consisting of amino, acylamino, diacylamino and nitro, pyridyl which may have a suitable substituent selected from the group consisting of lower alkoxy and halogen, pyrazinyl, pyrimidinyl, furyl, imidazolyl, naphthyl, N-(lower)- alkylindolyl or 3,4-methylenedioxyphenyl, and n is an integer of 0 to 3, or a group of the formula
  • R 11 is phenyl, phenoxy or phenyl(lower)alkoxy; or R 2 and R 3 in combination form a group of the formula
  • R 1 ° is hydrogen, lower alkyl or lower alkoxy; or a pharmaceutically acceptable salt thereof.
  • R 1 is indolyl which may have a suitable substituent selected from the group consisting of lower alkyl, phenyl, halogen, lower alkoxy, and nitro or benzofuranyl;
  • R 2 is hydrogen
  • R" is phenyl which may have suitable substituent(s) selected from the group consisting of trihalomethyl, nitro, cyano, imidazolyl, optionally protected hydroxy, acyl, amino, acylamino, diacylamino, di(lower)alkylamino, amino(lower)alkyl, acylamino(lower)alkyl, pyrazolyl, morpholinyl, piperidyl, triazolyl, lower alkoxy(lower)alkoxy, hydroxy(lower)alkyl, lower alkylpiperazinyl, phenyl and carboxy;
  • R 5 is hydrogen
  • Y is a group of the formula
  • R 6 is pyridyl which may have a suitable substituent selected from the group consisting of lower alkoxy and halogen, and n is an integer of 0 to 3; m is 0 or 1 ; and X is NR 9 in which R 9 is hydrogen, lower alkyl, cyclo(lower)alkyl or a group of the formula
  • R 1 ° is hydrogen, lower alkyl or lower alkoxy; or a pharmaceutically acceptable salt thereof.
  • the starting compound (430 mg) was dissolved in trifluoroacetic acid (1.5 ml) and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated, made basic with 1N sodium hydroxide solution and extracted three times with chloroform. The organic layer was dried over magnesium sulfate and filtered. Evaporation of the solvent gave the object compound as an oil (314 mg).
  • the starting compound (600 mg) was heated at 40°C for 2 hours in methyl iodide (10 ml). The reaction mixture was evaporated, and the residue was suspended in an aqueous sodium carbonate solution. The mixture was extracted with chloroform. The organic layer was washed successively with water and a saturated sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with a chloroform-methanol (20:1) as eluent to give the object compound as a pale yellow oily solid (376.5 mg). mp : 116-119°C MASS (ESI) (m/z) : 302 (M+H) +
  • the object compound was obtained according to a similar manner to that of Preparation 3 except that a mixutre of trifluoroacetic acid and dichloromethane was used instead of trifluoroacetic acid.
  • MASS 322 (M+1)
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • a solution of potassium tert-butoxide (4.2 g) in anhydrous tetrahydrofuran (70 ml) was cooled under nitrogen atmosphere to -70°C, and a solution of the starting compound (10 g) in anhydrous tetrahydrofuran (35 ml) was added while maintaining the reaction temperature at -70°C. After 30 minutes, this solution was added dropwise to a solution of 4-bromobenzoyl chloride (8.21 g) in anhydrous tetrahydrofuran (24 ml) with stirring while cooling at -70°C on a cooling bath. The reaction mixture was stirred at -70°C for 1 hour and quenched with 3N-hydrochloric acid (100 ml).
  • the cooling bath was removed and the reaction mixture was concentrated to dryness under reduced pressure.
  • the residue was dissolved in water (15 ml) and extracted with diethyl ether (twice).
  • the aqueous layer was concentrated in vaciio , and the residue was dissolved in anhydrous methanol.
  • the precipitated white solid (KCl) was removed by filtration.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 91.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 5.
  • the object compound was obtained according to a similar manner to that of Preparation 2.
  • the object compound was obtained according to a similar manner to that of Preparation 5 except that a mixture of dichloromethane and dimethylformamide was used instead of dichloromethane.

Abstract

Composé de formule (I) et sels pharmaceutiquement acceptables de ce composé. Dans ladite formule, chaque symbole est tel que défini dans la description. Le composé et les sels pharmaceutiquement acceptables considérés ont un fort effet inhibiteur sur la production d'oxyde nitrique (NO) et sont utiles pour prévenir et/ou traiter les maladies à médiation NO, chez l'homme et l'animal, à savoir par exemple: syndrome de détresse respiratoire aiguë de l'adulte, ischémie cardiovasculaire, myocardite, insuffisance cardiaque, synovite, choc, diabète, néphropathie diabétique, rétinopathie diabétique, neuropathie diabétique, glomérulonéphrite, ulcère gastroduodénal, maladie intestinale inflammatoire, infarctus cérébral, ischémie cérébrale, hémorragie cérébrale, migraine, polyarthrite rhumatoïde, goutte, névrite, algies postzostériennes, arthrose, ostéoporose, lupus érythémateux aigu disséminé, rejet d'une transplantation d'organe, asthme, métastase, maladie d'Alzheimer, arthrite, troubles du système nerveux central, dermatite, hépatite, cirrhose du foie, sclérose en plaques, pancréatite, athérosclérose et autres.
PCT/JP1997/004243 1996-12-16 1997-11-20 Nouveaux composes amide WO1998027108A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP52752898A JP2001505585A (ja) 1996-12-16 1997-11-20 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
AU49680/97A AU4968097A (en) 1996-12-16 1997-11-20 New amide compounds
EP97912529A EP0946587A2 (fr) 1996-12-16 1997-11-20 Nouveaux composes amide

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPO4219 1996-12-16
AUPO4219A AUPO421996A0 (en) 1996-12-16 1996-12-16 New amide compounds
AUPO5929A AUPO592997A0 (en) 1997-04-01 1997-04-01 New amide compounds
AUPO5929 1997-04-01
AUPO9030A AUPO903097A0 (en) 1997-09-09 1997-09-09 New amide compounds
AUPO9030 1997-09-09

Publications (2)

Publication Number Publication Date
WO1998027108A2 true WO1998027108A2 (fr) 1998-06-25
WO1998027108A3 WO1998027108A3 (fr) 1998-07-30

Family

ID=27157969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/004243 WO1998027108A2 (fr) 1996-12-16 1997-11-20 Nouveaux composes amide

Country Status (3)

Country Link
EP (1) EP0946587A2 (fr)
JP (1) JP2001505585A (fr)
WO (1) WO1998027108A2 (fr)

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051215A2 (fr) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Nouvelle utilisation
WO1999054314A1 (fr) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Nouveaux heterocycles a 5 noyaux a substitution diphenyle, leur procede de preparation et leur utilisation comme medicaments
WO1999057114A1 (fr) * 1998-05-04 1999-11-11 Fujisawa Pharmaceutical Co., Ltd. Derives de carboxamide heterocycliques utilisees comme inhibiteurs de la production de monoxyde d'azote
WO2000049015A1 (fr) * 1999-02-17 2000-08-24 Fujisawa Pharmaceutical Co., Ltd. Composes pyridine et leur utilisation pharmaceutique
WO2001002387A1 (fr) * 1999-07-05 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. N-imidazolylmethyl-carboxamides utilises comme inhibiteurs de la production d'oxyde nitrique
WO2001026656A2 (fr) * 1999-10-11 2001-04-19 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'heterocycles a 5 chainons et leur application comme inhibiteurs de monoamine oxydase
FR2812546A1 (fr) * 2000-08-01 2002-02-08 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
WO2003074517A1 (fr) * 2002-03-06 2003-09-12 Astrazeneca Ab Derives d'amido-indole possedant une activite d'inhibition de la glycogene phosphorylase
JP2003528871A (ja) * 2000-03-27 2003-09-30 シエーリング アクチエンゲゼルシャフト Ｎｏｓインヒビターとしてのｎ−複素環式誘導体
EP1387680A1 (fr) * 2001-03-05 2004-02-11 TransTech Pharma Inc. Agents th rapeutiques base de d riv s benzimidazole
EP1444204A1 (fr) * 2001-10-22 2004-08-11 The Research Foundation Of State University Of New York Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees
JP2004531526A (ja) * 2001-04-10 2004-10-14 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ５員複素間誘導体、その製造法及びその医薬としての使用
EP1487796A1 (fr) * 2002-03-28 2004-12-22 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
US6852725B1 (en) * 1998-06-12 2005-02-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. Imidazolyl derivatives
WO2006004924A2 (fr) * 2004-06-28 2006-01-12 Amgen Sf, Llc Composes imidazolo, compositions et leurs methodes d'utilisation
US7057051B2 (en) 2001-07-20 2006-06-06 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7115648B2 (en) 2002-03-06 2006-10-03 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7122567B2 (en) 2002-03-06 2006-10-17 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
AU2002224797B2 (en) * 2000-10-30 2006-10-26 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
US7129249B2 (en) 2002-03-06 2006-10-31 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
US7138415B2 (en) 2002-03-06 2006-11-21 Astrazeneca Ab Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
US7148225B2 (en) 2002-03-28 2006-12-12 Neurogen Corporation Substituted biaryl amides as C5A receptor modulators
US7169927B2 (en) 2002-03-06 2007-01-30 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
WO2007052073A2 (fr) * 2005-10-31 2007-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Derives d'amide de soufre et d'amide a heterocycle substitue utilises en tant qu'inhibiteurs d'histone desacetylase (hdac)
US7241790B2 (en) * 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
WO2008011557A2 (fr) * 2006-07-20 2008-01-24 Borchardt Allen J Inhibiteurs hétéroaryliques de la kinase rho
KR100822085B1 (ko) * 1999-10-11 2008-04-15 소시에떼 드 꽁세이으 드 르세르세 에 따블리까시옹 시앙띠피끄 (에스.세.에르.아.에스.) 5-원 헤테로사이클 유도체, 이의 제조 방법 및의약으로서의 이의 용도
US7381736B2 (en) 2004-09-02 2008-06-03 Metabasis Therapeutics, Inc. Thiazole and thiadiazole inhibitors of tyrosine phosphatases
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7566734B2 (en) 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
US7576221B2 (en) 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
US7626040B2 (en) 2005-08-09 2009-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole compounds as KSP inhibitors
US7626039B2 (en) 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
EP2188274A1 (fr) * 2007-08-03 2010-05-26 Boehringer Ingelheim International GmbH Inhibiteurs de polymerase virale
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen
US7772216B2 (en) 2001-10-22 2010-08-10 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7820646B2 (en) 2007-01-05 2010-10-26 Novartis Vaccines And Diagnostics, Inc. Cyclized derivatives as Eg-5 inhibitors
US7863294B2 (en) * 2004-12-10 2011-01-04 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Heterocycle derivatives as histone deacetylase (HDAC) inhibitors
US7884120B2 (en) 2002-08-19 2011-02-08 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US7901894B2 (en) 1999-01-13 2011-03-08 The Research Foundation Of State University Of New York Kinase inhibitors
WO2011084642A1 (fr) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Composé approprié pour le traitement de synucléopathies
US8148392B2 (en) 2005-05-25 2012-04-03 Lorus Therapeutics Inc. 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer
US8227462B2 (en) 2008-09-10 2012-07-24 Novartis Ag Pyrrolidine-1,2-dicarboxamide derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8354397B2 (en) 2001-07-27 2013-01-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP2546231A1 (fr) * 2010-03-04 2013-01-16 Ajinomoto Co., Inc. Dérivé d'alkylamine
US8404684B2 (en) 2003-05-02 2013-03-26 Novartis Ag Inhibitors of phosphatidylinositol 3-kinase
US8431575B2 (en) 2010-02-18 2013-04-30 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
WO2015142001A3 (fr) * 2014-03-21 2015-12-03 충남대학교산학협력단 Composé doté d'une action cardiotonique et composition pharmaceutique permettant de prévenir ou de traiter l'insuffisance cardiaque et contenant ledit composé
WO2016024587A1 (fr) * 2014-08-13 2016-02-18 日本曹達株式会社 Composé de diarylimidazole et agent de lutte antiparasitaire
CN105473575A (zh) * 2013-08-09 2016-04-06 埃科特莱茵药品有限公司 作为alx受体激动剂的苯并咪唑基-甲基脲衍生物
US9309247B2 (en) 2013-03-20 2016-04-12 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer
WO2017104741A1 (fr) 2015-12-16 2017-06-22 日本曹達株式会社 Composé de type arylazole et agent de lutte contre les organismes nuisibles
WO2017068089A3 (fr) * 2015-10-23 2017-07-27 Vifor (International) Ag Nouveaux inhibiteurs de la ferroportine
WO2018192973A1 (fr) 2017-04-18 2018-10-25 Vifor (International) Ag Sels inhibiteurs de ferroportine
US20190270729A1 (en) * 2016-06-21 2019-09-05 Shifa Biomedical Corporation Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US11104957B2 (en) 2013-10-04 2021-08-31 Aptose Biosciences, Inc. Compositions and methods for treating cancers
US11149047B2 (en) 2017-10-30 2021-10-19 Aptose Biosciences, Inc. Aryl imidazoles for treatment of cancer
CN113683598A (zh) * 2020-05-18 2021-11-23 成都先导药物开发股份有限公司 一种免疫调节剂
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521853A (ja) * 2004-12-02 2008-06-26 プロビオドルグ エージー 神経疾患治療用の新規化合物
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7990335B2 (en) 2007-12-05 2011-08-02 Antennas Direct, Inc. Antenna assemblies with antenna elements and reflectors
US8093243B2 (en) * 2008-02-12 2012-01-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
USD883265S1 (en) 2008-02-29 2020-05-05 Antennas Direct, Inc. Antenna

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491525A1 (fr) * 1990-12-18 1992-06-24 Eli Lilly And Company Benzamides et sulfonamides comme agents hypoglycémiques
WO1996016981A2 (fr) * 1994-12-02 1996-06-06 Fujisawa Pharmaceutical Co., Ltd. Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491525A1 (fr) * 1990-12-18 1992-06-24 Eli Lilly And Company Benzamides et sulfonamides comme agents hypoglycémiques
WO1996016981A2 (fr) * 1994-12-02 1996-06-06 Fujisawa Pharmaceutical Co., Ltd. Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 81, no. 7, 19 August 1974 Columbus, Ohio, US; abstract no. 37511r, HEINISCH G ET AL: "2-Dialkylaminoacylaminoimidazoles as potential local anesthetics." page 385; column 1; XP002057314 & SCI. PHARM., vol. 42, no. 1, 1974, pages 19-33, *
CROSS D F W ET AL: "Peptides. Part XIV. Thiazoleamino-acids, Degradation Products of Thiostrepton." JOURNAL OF THE CHEMICAL SOCIETY., April 1963, LETCHWORTH GB, pages 2143-2150, XP002057308 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Franfurt DE, XP002057315 & REV. ROUM. CHIM. , vol. 10, 1965, pages 617-620, *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Frankfurt DE, XP002057316 & STUD. UNIV. BABES-BOLYAI CHEM., vol. 1, 1960, page 155 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Frankfurt DE, XP002057317 & AM. CHEM. J., vol. 47, 1912, pages 234-236, *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Frankfurt DE, XP002057318 & TETRAHEDRON., vol. 30, 1974, OXFORD GB, pages 3859-3864, *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Frankfurt DE, XP002057319 & ARCH. PHARM., vol. 312, 1979, pages 198-205, *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Frankfurt DE, XP002057320 & CHEM. HETEROCYCL. COMPD. (ENGL. TRANSL.), vol. 6, 1970, pages 486-488, *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Frankfurt DE, XP002057321 & CHEM. PHARM. BULL., vol. 17, 1969, page 2381 *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Frankfurt DE, XP002057322 & SYNTH. COMMUN., vol. 18, no. 7, 1988, pages 651-658, *
DATABASE CROSSFIRE Beilstein Informationssysteme GmbH Frankfurt DE, XP002057323 & UKR. KHIM. ZH. (RUSS. ED.), vol. 21, 1955, pages 726-729, *
GERBERT U ET AL: "Model reactions for enzymic catalysis. IV. Structure-activity relationship of new transaminators with imidazole, thiazole, and benzimidazole skeletons" JUSTUS LIEBIGS ANN. CHEM. , no. 4, 1974, pages 644-654, XP002057306 *
GORDON T D ET AL: "Synthetic Approaches to the 'Azole' Peptide Mimetics" TETRAHEDRON LETTERS., vol. 34, no. 12, 19 March 1993, OXFORD GB, pages 1901-1904, XP002038851 *
HAMADA Y ET AL: "New methods and reagents in organic synthesis. 67. A general synthesis of derivatives of optically pure 2-(1-aminoalkyl)thiazole-4 -carboxylic acids" J. ORG. CHEM. , vol. 52, no. 7, 3 April 1987, pages 1252-1255, XP002057304 *
LI G ET AL: "Synthesis of a Directly Connected Thiazole-Oxazole Ring System Present in Microcin B17" J. ORG. CHEM. , vol. 61, no. 2, 26 January 1996, pages 778-780, XP002057303 *
LIEBSCHER J ET AL: "Formylation Products of Thioamides; Part 12. Synthesis of Thiazoles by the Reaction of S-Alkylated Thioamides or Thioureas with Acid Derivatives" SYNTHESIS., no. 4, April 1985, STUTTGART DE, pages 414-417, XP002057313 *
MOFFETT R B ET AL: "Antiulcer Agents. p-Aminobenzamido Aromatic Compounds" JOURNAL OF MEDICINAL CHEMISTRY., vol. 14, no. 10, October 1971, WASHINGTON US, pages 963-968, XP002057311 *
NAIR V ET AL: "Regioselective [4+2] and [2+2] Cycloadditions of 1-Azirines to Heterocumulenes. Formation and Rearrangements of the Cycloadducts" JOURNAL OF ORGANIC CHEMISTRY., vol. 39, no. 25, 13 December 1974, EASTON US, pages 3763-3767, XP002057312 *
PETTIT G R ET AL: "Antineoplastic agents. 109. Structural biochemistry. 24. Synthesis of the cyclo-Ä(gly)Thz-(R)- and (S)-(gln)Thz-L-Val-L-Leu-L -ProÜ isomers of dolastatin 3" J. ORG. CHEM. , vol. 50, no. 15, 26 July 1985, pages 2654-2659, XP002057305 *
PYL T ET AL: "Zur Darstellung von 7-Benzoylamino-pyrrolo[2.1-bÜthiazolen" JUSTUS LIEBIGS ANNALEN DER CHEMIE., vol. 676, 1964, WEINHEIM DE, pages 141-150, XP002057309 *
PYL T ET AL: "Zur Kenntnis der Imidazo[5.1-bÜthiazole" JUSTUS LIEBIGS ANNALEN DER CHEMIE., vol. 679, 1964, WEINHEIM DE, pages 144-150, XP002057310 *
See also references of EP0946587A2 *
SETO Y ET AL: "Unusual amino acids and their peptides. V. Synthesis and the absolute configuration of.beta.-(2-thiazolyl)-.beta.-alanine present in bottromycin" BULL. CHEM. SOC. JAP. , vol. 47, no. 1, January 1974, pages 151-155, XP002057307 *

Cited By (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
WO1999051215A3 (fr) * 1998-04-06 2000-03-09 Fujisawa Pharmaceutical Co Nouvelle utilisation
WO1999051215A2 (fr) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Nouvelle utilisation
WO1999054314A1 (fr) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Nouveaux heterocycles a 5 noyaux a substitution diphenyle, leur procede de preparation et leur utilisation comme medicaments
WO1999057114A1 (fr) * 1998-05-04 1999-11-11 Fujisawa Pharmaceutical Co., Ltd. Derives de carboxamide heterocycliques utilisees comme inhibiteurs de la production de monoxyde d'azote
US6852725B1 (en) * 1998-06-12 2005-02-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. Imidazolyl derivatives
US7238695B2 (en) 1998-06-12 2007-07-03 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Imidazolyl derivatives
US7901894B2 (en) 1999-01-13 2011-03-08 The Research Foundation Of State University Of New York Kinase inhibitors
US6521643B1 (en) 1999-02-17 2003-02-18 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds and their pharmaceutical use
WO2000049015A1 (fr) * 1999-02-17 2000-08-24 Fujisawa Pharmaceutical Co., Ltd. Composes pyridine et leur utilisation pharmaceutique
WO2001002387A1 (fr) * 1999-07-05 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. N-imidazolylmethyl-carboxamides utilises comme inhibiteurs de la production d'oxyde nitrique
EP1228760A2 (fr) * 1999-10-11 2002-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Dérivés d'hétérocycles à 5 chaínons, leur préparation et leur application à titre de médicaments
JP2003511416A (ja) * 1999-10-11 2003-03-25 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ５員複素環誘導体、その製造方法及びその医薬としての使用
AU783129B2 (en) * 1999-10-11 2005-09-29 Ipsen Pharma S.A.S. 5-membered heterocycle derivatives, production thereof and use thereof as medicaments
JP4972263B2 (ja) * 1999-10-11 2012-07-11 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ５員複素環誘導体、その製造方法及びその医薬としての使用
EP1228760A3 (fr) * 1999-10-11 2004-01-28 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Dérivés d'hétérocycles à 5 chaínons, leur préparation et leur application à titre de médicaments
WO2001026656A3 (fr) * 1999-10-11 2002-04-18 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons et leur application comme inhibiteurs de monoamine oxydase
KR100822085B1 (ko) * 1999-10-11 2008-04-15 소시에떼 드 꽁세이으 드 르세르세 에 따블리까시옹 시앙띠피끄 (에스.세.에르.아.에스.) 5-원 헤테로사이클 유도체, 이의 제조 방법 및의약으로서의 이의 용도
EP1589007A2 (fr) 1999-10-11 2005-10-26 Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS Dérivés d'hétérocycles à 5 chainons, leur préparation et leur application comme médicaments
CZ304331B6 (cs) * 1999-10-11 2014-03-05 Ipsen Pharma, S.A.S. Použití thiazolových derivátů pro přípravu léčiva
WO2001026656A2 (fr) * 1999-10-11 2001-04-19 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'heterocycles a 5 chainons et leur application comme inhibiteurs de monoamine oxydase
JP2003528871A (ja) * 2000-03-27 2003-09-30 シエーリング アクチエンゲゼルシャフト Ｎｏｓインヒビターとしてのｎ−複素環式誘導体
US7566734B2 (en) 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
US7638546B1 (en) 2000-08-01 2009-12-29 Ipsen Pharma S.A.S. Imidazolyl derivatives
FR2812546A1 (fr) * 2000-08-01 2002-02-08 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
EP1392291B1 (fr) * 2000-10-30 2007-05-30 Janssen Pharmaceutica N.V. Inhibiteurs de tripeptidyl peptidase
AU2002224797B2 (en) * 2000-10-30 2006-10-26 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
US7329684B2 (en) 2001-03-05 2008-02-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
EP1387680A1 (fr) * 2001-03-05 2004-02-11 TransTech Pharma Inc. Agents th rapeutiques base de d riv s benzimidazole
EP1387680A4 (fr) * 2001-03-05 2010-01-13 Transtech Pharma Inc Agents th rapeutiques base de d riv s benzimidazole
US7087632B2 (en) * 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
CZ304550B6 (cs) * 2001-04-10 2014-07-02 Ipsen Pharma, S.A.S. Deriváty heterocyklů s 5 atomy kruhu, jejich příprava a jejich použití jako léčiv
JP2004531526A (ja) * 2001-04-10 2004-10-14 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ５員複素間誘導体、その製造法及びその医薬としての使用
US7057051B2 (en) 2001-07-20 2006-06-06 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7572785B2 (en) 2001-07-20 2009-08-11 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US8354397B2 (en) 2001-07-27 2013-01-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US8772275B2 (en) 2001-07-27 2014-07-08 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US8088768B2 (en) 2001-10-22 2012-01-03 The Research Foundation Of The State University Of New York Protein kinase and phosphatase inhibitors
EP1444204A1 (fr) * 2001-10-22 2004-08-11 The Research Foundation Of State University Of New York Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees
US7427608B2 (en) 2001-10-22 2008-09-23 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
EP1444204A4 (fr) * 2001-10-22 2009-11-04 Univ New York State Res Found Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees
US7129225B2 (en) 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
US7772216B2 (en) 2001-10-22 2010-08-10 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7166636B2 (en) 2002-03-06 2007-01-23 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7122567B2 (en) 2002-03-06 2006-10-17 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
US7332515B2 (en) 2002-03-06 2008-02-19 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7169927B2 (en) 2002-03-06 2007-01-30 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
WO2003074517A1 (fr) * 2002-03-06 2003-09-12 Astrazeneca Ab Derives d'amido-indole possedant une activite d'inhibition de la glycogene phosphorylase
US7129249B2 (en) 2002-03-06 2006-10-31 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
US7115648B2 (en) 2002-03-06 2006-10-03 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7138415B2 (en) 2002-03-06 2006-11-21 Astrazeneca Ab Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
EP1487796A4 (fr) * 2002-03-28 2005-11-16 Neurogen Corp Biarylamides substitues en tant que modulateurs du recepteur c5a
EP1487796A1 (fr) * 2002-03-28 2004-12-22 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
US7148225B2 (en) 2002-03-28 2006-12-12 Neurogen Corporation Substituted biaryl amides as C5A receptor modulators
US7241790B2 (en) * 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
US8394815B2 (en) 2002-08-19 2013-03-12 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US7884120B2 (en) 2002-08-19 2011-02-08 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US8987305B2 (en) 2002-08-19 2015-03-24 Aptose Biosciences Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US8404684B2 (en) 2003-05-02 2013-03-26 Novartis Ag Inhibitors of phosphatidylinositol 3-kinase
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
US10080739B2 (en) 2003-11-14 2018-09-25 Aptose Biosciences Inc. Aryl imidazoles and their use as anti-cancer agents
US8716492B2 (en) 2004-06-15 2014-05-06 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US9617224B2 (en) 2004-06-15 2017-04-11 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US8101778B2 (en) 2004-06-15 2012-01-24 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US10112936B2 (en) 2004-06-15 2018-10-30 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US9079860B2 (en) 2004-06-15 2015-07-14 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US8318791B2 (en) 2004-06-18 2012-11-27 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
US8735599B2 (en) 2004-06-18 2014-05-27 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivates
US7576221B2 (en) 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
WO2006004924A2 (fr) * 2004-06-28 2006-01-12 Amgen Sf, Llc Composes imidazolo, compositions et leurs methodes d'utilisation
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
WO2006004924A3 (fr) * 2004-06-28 2006-03-09 Amgen Sf Llc Composes imidazolo, compositions et leurs methodes d'utilisation
US7381736B2 (en) 2004-09-02 2008-06-03 Metabasis Therapeutics, Inc. Thiazole and thiadiazole inhibitors of tyrosine phosphatases
US7863294B2 (en) * 2004-12-10 2011-01-04 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Heterocycle derivatives as histone deacetylase (HDAC) inhibitors
US8148392B2 (en) 2005-05-25 2012-04-03 Lorus Therapeutics Inc. 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer
US7626040B2 (en) 2005-08-09 2009-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole compounds as KSP inhibitors
WO2007052073A3 (fr) * 2005-10-31 2007-08-02 Angeletti P Ist Richerche Bio Derives d'amide de soufre et d'amide a heterocycle substitue utilises en tant qu'inhibiteurs d'histone desacetylase (hdac)
AU2006310257B2 (en) * 2005-10-31 2012-04-26 Msd Italia S.R.L. Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (HDAC) inhibitors
US8080573B2 (en) 2005-10-31 2011-12-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors
WO2007052073A2 (fr) * 2005-10-31 2007-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Derives d'amide de soufre et d'amide a heterocycle substitue utilises en tant qu'inhibiteurs d'histone desacetylase (hdac)
US7626039B2 (en) 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
US8252830B2 (en) 2005-12-14 2012-08-28 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
US7842708B2 (en) * 2005-12-14 2010-11-30 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
US8604056B2 (en) 2005-12-14 2013-12-10 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
WO2008011557A3 (fr) * 2006-07-20 2008-07-31 Allen J Borchardt Inhibiteurs hétéroaryliques de la kinase rho
WO2008011557A2 (fr) * 2006-07-20 2008-01-24 Borchardt Allen J Inhibiteurs hétéroaryliques de la kinase rho
US7820646B2 (en) 2007-01-05 2010-10-26 Novartis Vaccines And Diagnostics, Inc. Cyclized derivatives as Eg-5 inhibitors
EP2188274A1 (fr) * 2007-08-03 2010-05-26 Boehringer Ingelheim International GmbH Inhibiteurs de polymerase virale
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2188274A4 (fr) * 2007-08-03 2011-05-25 Boehringer Ingelheim Int Inhibiteurs de polymerase virale
US8541402B2 (en) 2007-12-19 2013-09-24 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8912182B2 (en) 2007-12-19 2014-12-16 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
US8476268B2 (en) 2008-09-10 2013-07-02 Novartis Ag Pyrrolidine-1,2-dicarboxamide derivatives
US8710085B2 (en) 2008-09-10 2014-04-29 Novartis Ag Pyrrolidine-1,2-dicarboxamide derivatives
US8227462B2 (en) 2008-09-10 2012-07-24 Novartis Ag Pyrrolidine-1,2-dicarboxamide derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US10363241B2 (en) 2009-09-30 2019-07-30 Vtv Therapeutics Llc Substituted imidazole derivatives and methods of use thereof
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
US9598375B2 (en) 2009-09-30 2017-03-21 Vtv Therapeutics Llc Substituted imidazole derivatives and methods of use thereof
US8846682B2 (en) 2009-12-16 2014-09-30 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
WO2011084642A1 (fr) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Composé approprié pour le traitement de synucléopathies
US9045461B2 (en) 2010-02-18 2015-06-02 Transtech Pharma, Llc Phenyl-heteroaryl derivatives and methods of use thereof
US8431575B2 (en) 2010-02-18 2013-04-30 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
US8741900B2 (en) 2010-02-18 2014-06-03 Transtech Pharma, Llc Phenyl-heteroaryl derivatives and methods of use thereof
EP2546231A1 (fr) * 2010-03-04 2013-01-16 Ajinomoto Co., Inc. Dérivé d'alkylamine
US9561216B2 (en) 2010-03-04 2017-02-07 Ea Pharma Co., Ltd. Alkylamine derivative
US9253997B2 (en) 2010-03-04 2016-02-09 Ajinomoto Co., Inc. Alkylamine derivative
EP2546231A4 (fr) * 2010-03-04 2014-04-30 Ajinomoto Kk Dérivé d'alkylamine
USRE49569E1 (en) 2010-03-04 2023-07-04 Ea Pharma Co., Ltd. Alkylamine derivative
KR20150002891A (ko) * 2010-03-04 2015-01-07 아지노모토 가부시키가이샤 알킬아민 유도체
US9309247B2 (en) 2013-03-20 2016-04-12 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer
CN105473575A (zh) * 2013-08-09 2016-04-06 埃科特莱茵药品有限公司 作为alx受体激动剂的苯并咪唑基-甲基脲衍生物
CN105473575B (zh) * 2013-08-09 2017-11-24 爱杜西亚药品有限公司 作为alx受体激动剂的苯并咪唑基‑甲基脲衍生物
US11104957B2 (en) 2013-10-04 2021-08-31 Aptose Biosciences, Inc. Compositions and methods for treating cancers
WO2015142001A3 (fr) * 2014-03-21 2015-12-03 충남대학교산학협력단 Composé doté d'une action cardiotonique et composition pharmaceutique permettant de prévenir ou de traiter l'insuffisance cardiaque et contenant ledit composé
JP2020114827A (ja) * 2014-08-13 2020-07-30 日本曹達株式会社 ジアリールイミダゾール化合物および有害生物防除剤
EP3766871A1 (fr) 2014-08-13 2021-01-20 Nippon Soda Co., Ltd. Composé de diarylimidazole et agent de lutte antiparasitaire
KR102447094B1 (ko) * 2014-08-13 2022-09-23 닛뽕소다 가부시키가이샤 디아릴이미다졸 화합물 및 유해 생물 방제제
WO2016024587A1 (fr) * 2014-08-13 2016-02-18 日本曹達株式会社 Composé de diarylimidazole et agent de lutte antiparasitaire
US10021880B2 (en) 2014-08-13 2018-07-17 Nippon Soda Co., Ltd. Diarylimidazole compound and harmful organism control agent
CN106573894A (zh) * 2014-08-13 2017-04-19 日本曹达株式会社 二芳基咪唑化合物和有害生物防除剂
JPWO2016024587A1 (ja) * 2014-08-13 2017-05-25 日本曹達株式会社 ジアリールイミダゾール化合物および有害生物防除剤
KR20170040243A (ko) 2014-08-13 2017-04-12 닛뽕소다 가부시키가이샤 디아릴이미다졸 화합물 및 유해 생물 방제제
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017068089A3 (fr) * 2015-10-23 2017-07-27 Vifor (International) Ag Nouveaux inhibiteurs de la ferroportine
US10738041B2 (en) 2015-10-23 2020-08-11 Vifor (International) Ag Ferroportin inhibitors
US11066399B2 (en) 2015-10-23 2021-07-20 Vifor (International) Ag Ferroportin inhibitors
US11001579B2 (en) 2015-10-23 2021-05-11 Vifor (International) Ag Ferroportin inhibitors
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11884633B2 (en) 2015-12-16 2024-01-30 Nippon Soda Co., Ltd. Arylazole compound and pest control agent
KR20210094161A (ko) 2015-12-16 2021-07-28 닛뽕소다 가부시키가이샤 아릴아졸 화합물 및 유해 생물 방제제
US11180456B2 (en) 2015-12-16 2021-11-23 Nippon Soda Co., Ltd. Arylazole compound and pest control agent
WO2017104741A1 (fr) 2015-12-16 2017-06-22 日本曹達株式会社 Composé de type arylazole et agent de lutte contre les organismes nuisibles
KR20180095813A (ko) 2015-12-16 2018-08-28 닛뽕소다 가부시키가이샤 아릴아졸 화합물 및 유해 생물 방제제
EP3872068A1 (fr) 2015-12-16 2021-09-01 Nippon Soda Co., Ltd. Composé de type arylazole et agent de lutte contre les organismes nuisibles
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US11866435B2 (en) 2015-12-22 2024-01-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US20200262822A1 (en) * 2016-06-21 2020-08-20 Shifa Biomedical Corporation Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases
US10947220B2 (en) * 2016-06-21 2021-03-16 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
US20190270729A1 (en) * 2016-06-21 2019-09-05 Shifa Biomedical Corporation Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases
US10899748B2 (en) * 2016-06-21 2021-01-26 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US11787793B2 (en) 2016-12-22 2023-10-17 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11339149B2 (en) 2016-12-22 2022-05-24 Incyte Corporation Heterocyclic compounds as immunomodulators
US11129820B2 (en) 2017-04-18 2021-09-28 Vifor (International) Ag Ferroportin-inhibitor salts
WO2018192973A1 (fr) 2017-04-18 2018-10-25 Vifor (International) Ag Sels inhibiteurs de ferroportine
US11149047B2 (en) 2017-10-30 2021-10-19 Aptose Biosciences, Inc. Aryl imidazoles for treatment of cancer
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11124511B2 (en) 2018-03-30 2021-09-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US11414433B2 (en) 2018-05-11 2022-08-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US10906920B2 (en) 2018-05-11 2021-02-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂
CN113683598A (zh) * 2020-05-18 2021-11-23 成都先导药物开发股份有限公司 一种免疫调节剂
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof

Also Published As

Publication number Publication date
JP2001505585A (ja) 2001-04-24
WO1998027108A3 (fr) 1998-07-30
EP0946587A2 (fr) 1999-10-06

Similar Documents

Publication Publication Date Title
WO1998027108A2 (fr) Nouveaux composes amide
JP7352662B2 (ja) ベンゾイソオキサゾールスルホンアミド誘導体
CN114269735B (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
EP1720864B1 (fr) Derives de thiophene a substitution benzimidazole a activite sur ikk3
US7265120B2 (en) Pyrazine derivatives and pharmaceutical use thereof
JP4625969B2 (ja) ベンズアミド誘導体
AU2018236290B2 (en) MK2 inhibitors, synthesis thereof, and intermediates thereto
EP0596406A1 (fr) Imidazo (1,2-a) pyridines comme antagonistes de la bradykinine
AU2014244555A1 (en) DNA-PK inhibitors
WO1997045425A1 (fr) Nouveaux carboxamides d'indolyle et de benzofuranyle utilises comme inhibiteurs de la production d'oxyde nitrique
EP2788349A1 (fr) Inhibiteurs de kinases
EP2297112A1 (fr) Composés de pyrazole comme antagonistes de ccr1
AU2007207671A1 (en) Compounds for the treatment of inflammatory disorders
CN114423751B (zh) 用作选择性aurora a抑制剂的新型杂环化合物
WO2006059164A2 (fr) Amides d'acide pyrrolopyridine-2-carboxylique
CN112673001A (zh) 作为激酶抑制剂的吲唑甲酰胺
US8765739B2 (en) Azetidine compound and pharmaceutical use thereof
WO2006056815A1 (fr) Amides d'acide indole-2-carboxylique
EP1075475B1 (fr) Derives de carboxamides heterocycliques en tant que inhibiteurs de la production du monoxyde d'azote
EP2459551B1 (fr) Dihydrobenzoindazoles
JP2003503489A (ja) 一酸化窒素産生阻害剤としてのｎ−イミダゾリルメチルカルボキサミド
JPH1045751A (ja) 新規ピペラジン化合物
JPH1081671A (ja) 新規ペプチド化合物
CN117561262A (zh) 大环tak1抑制剂
WO1997017349A1 (fr) Derives heterocycliques fusionnes pentagonaux d'azepine et leur emploi pharmaceutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN HU IL JP KR MX US AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN HU IL JP KR MX US AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 1998 527528

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09319914

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1997912529

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997912529

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997912529

Country of ref document: EP